Hangzhou Fortune Gas Cryogenic Group (603173) Fair Value & Analysis
Industrials · CN · Market cap 5.5B CNY
Analysis
Hangzhou Fortune Gas Cryogenic Group (603173) currently trades at ¥35.70, while our model-based Fair Value estimate is ¥55.30 — implying the stock looks roughly 54.9% undervalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Hangzhou Fortune Gas Cryogenic Group Co., Ltd. engages in the research, design, and complete service of various industrial gas cryogenic technologies, natural gas treatment and liquefaction technologies, and technologies related to syngas and hydrogen. It offers turnkey; spare parts, remote support, and personnel dispatch; and installation supervision, commissioning, and operation grantee services. The company also provides air separation units, and liquid air separation unit; rare gases, such as krypton/xenon, helium/neon, and helium extraction and liquefaction; and coil-wound heat exchanger, cold box, vacuum cryogenic storage tank, and vaporizer. It serves energy and resources, chemical, materials, environmental protection, pulp and paper, electronics, machinery, and construction industries. The company operates in the United States, Japan, South Korea, India, Europe, the Commonwealth of Independent States, the Middle East, Southeast Asia, Africa, and Latin America. The company wa…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.